[1]吴华国,张 慧.靶向survivin克服肿瘤耐药的研究进展[J].中国药理学通报,2018,(09):1189-1192.[doi:10.3969/j.issn.1001-1978.2018.09.002]
 WU Hua-guo,ZHANG Hui.New strategy for antagonizing drug resistance: targeting survivin[J].Chinese Pharmacological Bulletin,2018,(09):1189-1192.[doi:10.3969/j.issn.1001-1978.2018.09.002]
点击复制

靶向survivin克服肿瘤耐药的研究进展()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2018年09期
页码:
1189-1192
栏目:
讲座与综述
出版日期:
2018-08-26

文章信息/Info

Title:
New strategy for antagonizing drug resistance: targeting survivin
文章编号:
1001-1978(2018)09-1189-04
作者:
吴华国1张 慧2
山东省肿瘤防治研究院1.头颈外科、2.肿瘤内科,山东 济南 250117
Author(s):
WU Hua-guo1 ZHANG Hui2
1.Dept of Head and Neck Surgery; 2.Dept of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan 250117, China
关键词:
肿瘤 化疗 多药耐药 survivin 凋亡抑制蛋白家族 靶向
Keywords:
tumor chemotherapy multidrug resistance survivin inhibitor of apoptosis proteins(IAP)family targeting
分类号:
R-05; R341; R329.25; R730.5; R977.6
DOI:
10.3969/j.issn.1001-1978.2018.09.002
文献标志码:
A
摘要:
肿瘤病人对化疗药物的多药耐药是化疗失败的主要原因,survivin是凋亡抑制蛋白家族的新成员,几乎在所有肿瘤组织中表达水平增加,是参与肿瘤多药耐药性最重要的分子之一。因此,抑制survivin的作用或者降低其表达水平是克服肿瘤多药耐药的有效策略。该文重点综述survivin参与肿瘤细胞耐药的作用和靶向survivin克服肿瘤耐药的研究进展。
Abstract:
Multidrug resistance(MDR)often leads to failure of cancer chemotherapy. survivin, a member of the inhibitor of apoptosis proteins(IAP)family, is overexpressed in almost all kinds of tumor cells. Importantly, survivin has been identified as one of the most important molecules involved in the regulation of MDR. Therefore, inhibiting the activity of survivin or down-regulating the expression of survivin might be an effective strategy to overcome tumor MDR. In this article, the roles of survivin involved in the development of drug resistance and the strategies to overcome drug resistance by targeting survivin are thus reviewed.

参考文献/References:

[1] Ambrosini G, Adida C, Altieri D C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma[J]. Nat Med, 1997, 3(8): 917-21.
[2] Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy[J]. Int J Mol Sci, 2014, 15(2): 2494-516.
[3] Jutzy J M, Khan S, Asuncion-Valenzuela M M, et al. Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro[J]. Cancer Microenviron, 2013, 6(1): 57-68.
[4] Roy K, Kanwar R K, Krishnakumar S, et al. Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model[J]. Int J Nanomedicine, 2015, 10: 1019-43.
[5] Salzano G, Navarro G, Trivedi M S, et al. Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer[J]. Mol Cancer Ther, 2015, 14(4): 1075-84.
[6] Caldas H, Jiang Y, Holloway M P, et al. Survivin splice variants regulate the balance between proliferation and cell death[J]. Oncogene, 2005, 24(12): 1994-2007.
[7] Hu D, Liu S, Shi L, et al. Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein(XIAP)complex to free caspase activity leading to cytolysis of target tumor cells[J]. J Biol Chem, 2010, 285(24): 18326-35.
[8] Chettiar S N, Cooley J V, Park I H, et al. Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle[J]. Bioorg Med Chem Lett, 2013, 23(19): 5429-33.
[9] Altieri D C. Survivin, versatile modulation of cell division and apoptosis in cancer[J]. Oncogene, 2003, 22(53): 8581-9.
[10] Takeno S, Yamashita S, Takahashi Y, et al. Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression[J]. Eur J Cardiothorac Surg, 2010, 37(2): 440-5.
[11] Bhanot U, Heydrich R, Moller P, et al. survivin expression in pancreatic intraepithelial neoplasia(PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma[J]. Am J Surg Pathol, 2006, 30(6): 754-9.
[12] 谷满仓,钱亚芳,孙 悦,等. 薏苡仁脂调控凋亡相关蛋白Bax、Bcl-2及survivin增强胰腺癌细胞对吉西他滨敏感性的研究[J]. 中国药理学通报, 2013, 29(4): 491-5.
[12] Gu M C,Qian Y F, Sun Y,et al. Coix seed lipids sensitize the activity of gemcitabine against pancreatic cancer cells through modulating Bax, Bcl-2 and survivin[J]. Chin Pharmacol Bull,2013, 29(4): 491-5.
[13] Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis[J]. Cancer, 2001, 91(11): 2026-32.
[14] Fukuda S, Pelus L M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+)cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis[J]. Blood, 2001, 98(7): 2091-100.
[15] Liu J L, Wang Y, Jiang J, et al. Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA[J]. Chin Med J(Engl), 2010, 123(20): 2901-7.
[16] Tran J, Master Z, Yu J L, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF[J]. Proc Natl Acad Sci USA, 2002, 99(7): 4349-54.
[17] Tsubaki M, Takeda T, Ogawa N, et al. Overexpression of survivin via activation of ERK1/2, Akt, and NF-kappaB plays a central role in vincristine resistance in multiple myeloma cells[J]. Leuk Res, 2015, 39(4): 445-52.
[18] Bhattacharyya J, Mihara K, Ohtsubo M, et al. Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression[J]. Cancer Sci, 2012, 103(1): 34-41.
[19] Nestal D M G, Silva K L, Vasconcelos F C, et al. survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells[J]. Oncol Rep, 2011,25(6): 1613-9.
[20] Singh N, Krishnakumar S, Kanwar R K, et al. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers[J]. Drug Discov Today,2015, 20(5): 578-87.
[21] Imai Y, Yamagishi H, Ono Y, et al. Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells[J]. Clin Transl Med, 2012, 1(1): 24.
[22] El D N, Abdelzaher E. Stem cell markers OCT4 and nestin in laryngeal squamous cell carcinoma and their relation to survivin expression[J]. Pathol Res Pract, 2014, 210(11): 751-8.
[23] Feng R, Dong L. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells[J]. Int J Clin Exp Pathol, 2015, 8(6): 6107-16.
[24] Hilovska L, Jendzelovsky R, Jendzelovska Z, et al. Downregulation of BCRP and anti-apoptotic proteins by proadifen(SKF-525A)is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells[J]. Int J Oncol, 2015, 47(4): 1572-84.
[25] Hofmann U B, Voigt H, Andersen M H, et al. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes[J]. Eur J Immunol, 2009, 39(5): 1419-24.

相似文献/References:

[1]刘红椿,杜晓光,耿美玉.锌依赖的组蛋白去乙酰化酶选择性抑制剂研究进展[J].中国药理学通报,2010,(08):0.
 LIU Hong chun,DU Xiao guang,GENG Mei yu.New advances in isoformselective inhibitors of Zn2+dependent histone deacetylase[J].Chinese Pharmacological Bulletin,2010,(09):0.
[2]董宪喆,张鹏,毕明刚.丝/苏氨酸激酶PLK1研究进展[J].中国药理学通报,2010,(03):289.
 DONG Xian zhe,ZHANG Peng,BI Ming gang.Research progress on serine/threonine kinase PLK1[J].Chinese Pharmacological Bulletin,2010,(09):289.
[3]胡世莲.褪黑素抗肿瘤作用及其机制的研究进展[J].中国药理学通报,2008,(04):0.
 HU Shi lian.Melatonin in the treatment of cancer and its mechanism[J].Chinese Pharmacological Bulletin,2008,(09):0.
[4]李德冠,孟爱民.造血干细胞衰老机制研究[J].中国药理学通报,2008,(06):0.
 LI De guan,MENG Ai min.Hematopoietic stem cell senescence[J].Chinese Pharmacological Bulletin,2008,(09):0.
[5]刘新艳,余清声,余红娥,等.中华眼镜蛇毒活性组分诱导内皮细胞凋亡[J].中国药理学通报,2008,(06):0.
 LIU Xin yan,YU Qing sheng,YU Hong e,et al.China cobra venom active factor can induce apoptosis of endothelial cells[J].Chinese Pharmacological Bulletin,2008,(09):0.
[6]杜晶,张励才.TRPM8的研究进展[J].中国药理学通报,2008,(09):0.
[7]张祖斌,顾振纶,蒋小岗,等.smiRNA在肿瘤及肿瘤干细胞中作用的研究进展[J].中国药理学通报,2009,(03):0.
 ZHANG Zu bin,GU Zhen lun,JIANG Xiao gang.The role of miRNAs in the tumor and tumor stem cells[J].Chinese Pharmacological Bulletin,2009,(09):0.
[8]李礼,李静,耿美玉.蛋白激酶C在肿瘤中的作用及其抑制剂研究进展[J].中国药理学通报,2009,(06):0.
 LI Li,LI Jing,GENG Mei yu.The role of protein kinase C in cancer and the progress of inhibitors targeting protein kinase C[J].Chinese Pharmacological Bulletin,2009,(09):0.
[9]刘萍,李静.灵菌红素体外对肿瘤转移相关生物学行为的影响[J].中国药理学通报,2010,(04):501.
 LIU Ping,LI Jing.The effects of Metacycloprodigiosin on tumor metastasisassociated cell behavior in vitro[J].Chinese Pharmacological Bulletin,2010,(09):501.
[10]张燕,肖婷婷,沈祥春.金属硫蛋白的功能及药理作用研究进展[J].中国药理学通报,2010,(06):821.
 ZHANG Yan,XIAO Ting ting,SHEN Xiang chun.The advance role and pharmacological effects of metallothionein[J].Chinese Pharmacological Bulletin,2010,(09):821.

备注/Memo

备注/Memo:
收稿日期:2018-04-10,修回日期:2018-05-20
基因项目:自然科学基金资助项目(No 8150111724); 山东省博士基金资助项目(No 2015BSC03007); 山东省医科院基金资助项目(No 2014-42)
作者简介:吴华国(1990-),男,硕士,住院医师,研究方向:肿瘤药理学,E-mail whg2007@aliyun.com;
张 慧(1986-),女,博士,主治医师,硕士生导师,研究方向:肿瘤个体化治疗,通讯作者,Tel:0531-67626912,E-mail:hui8942615@163.com
更新日期/Last Update: 2018-08-26